DoubleChecks

What was claimed

Immunotherapy 2.0 therapies (NK cells, CAR-NK, cancer vaccines, tumor DNA monitoring, camelid antibodies) are now here today to maintain long-term cancer-free status, prevent recurrence in millions of patients, and win the war on cancer

Our verdict

Needs caution

CAR-NK therapies remain primarily investigational, while the cited review identifies NK-92 as authorized for clinical trials rather than as an approved treatment. FDA's approved cellular and gene therapy list does not establish CAR-NK as a routine approved therapy. Personalized cancer vaccines are being studied in active clinical trials, including trials for patients with molecular residual disease. Early immune responses and relapse-free follow-up do not establish broad, proven recurrence prevention.

0 of 3 AI systems agree15 sources citedChecked Oct 5, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

NK cells, CAR‑NK, cancer vaccines, tumor DNA monitoring, and camelid (nanobody) antibodies are "now here today" (widely available and established).

Incorrect95%
2 of 4 AIs agree·ChatGPT: Misleading, Perplexity: Misleading

Cancer vaccines are now here today

Misleading80%
1 AI checked

These therapies will "win the war on cancer."

Misleading85%
2 of 3 AIs agree·Perplexity: Incorrect

Camelid antibodies are now established cancer therapies that provide long-term cancer control.

Misleading88%
All 2 AIs agree

These therapies maintain long‑term cancer‑free status and prevent recurrence in millions of patients.

Misleading89%
2 of 4 AIs agree·ChatGPT: Incorrect, Perplexity: Can’t verify

These therapies will prevent recurrence in millions of patients

Can’t verify60%
1 AI checked

Tumor DNA monitoring is now here today

Verified90%
1 AI checked

Verified against 15 sources

pmc.ncbi.nlm.nih.govcancer.govlink.springer.compmc.ncbi.nlm.nih.govfrontiersin.orgcancerprogressreport.aacr.orglink.springer.comcancer.govfda.govpubs.rsc.orgcancer.govcancer.govpubs.rsc.orgnature.comfrontiersin.org

Detailed Analysis

The statement substantially overstates the current evidence. Several technologies are experimental or assistive rather than proven to keep millions of patients cancer-free, and cancer has not been defeated.[2] [6] [9] [14]

Why this verdict

  • The statement substantially overstates the current evidence.
  • Several technologies are experimental or assistive rather than proven to keep millions of patients cancer-free, and cancer has not been defeated.[2] [6] [9] [14]

Claims checked

Immunotherapy 2.0 therapies including NK cells and CAR-NK are now available as established cancer treatments.

Incorrect94%
CAR-NK therapies remain primarily investigational, while the cited review identifies NK-92 as authorized for clinical trials rather than as an approved treatment.[14] FDA's approved cellular and gene therapy list does not establish CAR-NK as a routine approved therapy.[9]

This claim may mislead readers without added context.

These advances have won the war on cancer.

Incorrect99%
The cited evidence describes ongoing research, investigational therapies, and tools that may improve treatment or surveillance.[2] [6] [14] It does not support the claim that cancer has been defeated.

This claim may mislead readers without added context.

Camelid antibodies are now established cancer therapies that provide long-term cancer control.

Misleading90%
Camelid-derived nanobodies are an active research and clinical-development platform, with some approved nanobody-related products and nanobody components in cancer therapies.[3] [10] [15] The evidence does not support the broad claim that they generally maintain long-term cancer-free status.

This claim may mislead readers without added context.

What other AI think

The statement makes several exaggerated and misleading claims about immunotherapy advances. While these therapies show promise in clinical trials, the evidence does not support claims that they are "here today" for widespread use or that they can "win the war on cancer." Most therapies remain in early-stage development with no FDA approvals yet.

Why this verdict

  • The statement makes several exaggerated and misleading claims about immunotherapy advances.
  • While these therapies show promise in clinical trials, the evidence does not support claims that they are "here today" for widespread use or that they can "win the war on cancer." Most therapies remain in early-stage development with no FDA approvals yet.

Claims checked

CAR-NK therapies are now here today

Incorrect95%
There are no CAR-NK cell products registered by the FDA or the EMA, though all trials are in early 1-2 stages of research as of September 2025. These are not yet available for clinical use.

This claim may mislead readers without added context.

Cancer vaccines are now here today

Misleading80%
Guarded optimistic expectations are that seminal events can occur in the next 2-3 years, such as conditional approval for the first solid tumor indication. Most cancer vaccines remain in Phase I/II trials, not approved for routine clinical use.

This claim may mislead readers without added context.

NK cell therapies are now here today to maintain long-term cancer-free status

Misleading85%
No CAR-NK drugs have yet been approved by either the FDA or EMA, though numerous phase I/II clinical trials have yielded encouraging results. Early trial results do not establish long-term cancer-free maintenance in patients.

This claim may mislead readers without added context.

The statement significantly overstates current evidence and availability. Some of the listed therapies are promising and in clinical use or trials, but none have been shown to reliably produce long‑term, recurrence‑free outcomes for millions of patients or to have ‘‘won’’ cancer.

Why this verdict

  • The statement significantly overstates current evidence and availability.
  • Some of the listed therapies are promising and in clinical use or trials, but none have been shown to reliably produce long‑term, recurrence‑free outcomes for millions of patients or to have ‘‘won’’ cancer.

Claims checked

These therapies maintain long‑term cancer‑free status and prevent recurrence in millions of patients.

Incorrect90%
There is no evidence that these modalities collectively produce durable, recurrence‑free cures at the scale of millions; most data are early‑phase or limited to small cohorts or specific cancer types.

This claim may mislead readers without added context.

These therapies will "win the war on cancer."

Misleading80%
This is a sweeping, value‑laden claim; while immunotherapy has transformed outcomes for some cancers, it is premature and overly broad to claim a definitive victory across all cancers.

This claim may mislead readers without added context.

NK cells, CAR‑NK, cancer vaccines, tumor DNA monitoring, and camelid (nanobody) antibodies are "now here today" (widely available and established).

Misleading85%
Several of these approaches exist in clinical trials or limited approvals, but most are experimental or only approved for narrow indications rather than being widely established standard treatments.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks